Vaccines Market

Executive Summary

Vaccines Market was valued at US $67.72 billion in 2021 and is projected to grow at 10.95% CAGR over the forecast period to reach US $126.30 billion by 2027. Vaccines Market represented US $12.70 billion opportunity over 2019-2021 and estimated to create US $58.57 billion opportunity in 2027 over 2021.

Vaccines from Consainsights analyses the Vaccines Market in the Life Sciences industry over the forecast period to 2027.

Vaccines research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Vaccines segmentation includes Technology, Type, Disease Indication, Route of Administration, Patient Type, Region and Geography.

Based on the Technology, the Vaccines analysis covers Conjugate Vaccines, Inactivated & Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Toxoid Vaccines.

In Technology segment, Inactivated & Subunit Vaccines segment has highest cagr growth of 9.67%.

Based on the Type, the Vaccines analysis covers Monovalent Vaccines, Multivalent Vaccines.

In Type segment, Monovalent Vaccines segment has highest cagr growth of 9.67%.

Based on the Disease Indication, the Vaccines analysis covers Pneumococcal Disease, DTP, Influenza, HPV, Meningococcal Disease, Polio, Hepatitis, Rotavirus, MMR, Varicella, Herpes Zoster, Other Disease Indications.

In Disease Indication segment, Pneumococcal Disease segment has highest cagr growth of 9.67%.

Based on the Route of Administration, the Vaccines analysis covers Intramuscular and Subcutaneous Administration, Oral Administration, Other Routes of Administration.

In Route of Administration segment, Oral Administration segment has highest cagr growth of 9.67%.

Based on the Patient Type, the Vaccines analysis covers Pediatric Patients, Adult Patients.

In Patient Type segment, Pediatric Patients segment has highest cagr growth of 9.67%.

Based on the Region, the Vaccines analysis covers North America, Europe, Asia, Rest of the World.

In Region segment, Europe segment has highest cagr growth of 9.67%.

Based on the region, the Vaccines analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Glaxosmithkline PLC, Pfizer, Inc, Merck & Co., Inc, Sanofi Pasteur SA, CSL Limited, Emergent Biosolutions, Inc, Johnson & Johnson, Astrazeneca, Serum Institute of India Pvt., LTD, Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company, Limited, Panacea Biotec, LTD, Biological E, Bharat Biotech, Other Companies and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Technology

Introduction

In 2021, Conjugate Vaccines segment has the highest revenue of US $27.28 billion and is expected to grow at CAGR of 9.67% by 2027 Inactivated & Subunit Vaccines segment has highest cagr growth of 9.67%.

Conjugate Vaccines

Conjugate Vaccines segment was valued at US $22.16 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $50.88 billion by 2027. Conjugate Vaccines segment represented US $5.12 billion opportunity over 2019-2021 and estimated to create US $23.60 billion opportunity in 2027 over 2021.

Inactivated & Subunit Vaccines

Inactivated & Subunit Vaccines segment was valued at US $12.18 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $27.95 billion by 2027. Inactivated & Subunit Vaccines segment represented US $2.81 billion opportunity over 2019-2021 and estimated to create US $12.96 billion opportunity in 2027 over 2021.

Live Attenuated Vaccines

Live Attenuated Vaccines segment was valued at US $10.82 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $24.83 billion by 2027. Live Attenuated Vaccines segment represented US $2.50 billion opportunity over 2019-2021 and estimated to create US $11.52 billion opportunity in 2027 over 2021.

Recombinant Vaccines

Recombinant Vaccines segment was valued at US $5.15 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $11.83 billion by 2027. Recombinant Vaccines segment represented US $1.19 billion opportunity over 2019-2021 and estimated to create US $5.49 billion opportunity in 2027 over 2021.

Toxoid Vaccines

Toxoid Vaccines segment was valued at US $4.71 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $10.80 billion by 2027. Toxoid Vaccines segment represented US $1.09 billion opportunity over 2019-2021 and estimated to create US $5.01 billion opportunity in 2027 over 2021.

Type

Introduction

In 2021, Monovalent Vaccines segment has the highest revenue of US $50.41 billion and is expected to grow at CAGR of 9.67% by 2027 Monovalent Vaccines segment has highest cagr growth of 9.67%.

Monovalent Vaccines

Monovalent Vaccines segment was valued at US $40.96 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $94.02 billion by 2027. Monovalent Vaccines segment represented US $9.46 billion opportunity over 2019-2021 and estimated to create US $43.61 billion opportunity in 2027 over 2021.

Multivalent Vaccines

Multivalent Vaccines segment was valued at US $14.06 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $32.28 billion by 2027. Multivalent Vaccines segment represented US $3.25 billion opportunity over 2019-2021 and estimated to create US $14.97 billion opportunity in 2027 over 2021.

Disease Indication

Introduction

In 2021, Pneumococcal Disease segment has the highest revenue of US $25.97 billion and is expected to grow at CAGR of 9.67% by 2027 Pneumococcal Disease segment has highest cagr growth of 9.67%.

Pneumococcal Disease

Pneumococcal Disease segment was valued at US $21.10 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $48.43 billion by 2027. Pneumococcal Disease segment represented US $4.87 billion opportunity over 2019-2021 and estimated to create US $22.46 billion opportunity in 2027 over 2021.

DTP

DTP segment was valued at US $12.99 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $29.81 billion by 2027. DTP segment represented US $3.00 billion opportunity over 2019-2021 and estimated to create US $13.83 billion opportunity in 2027 over 2021.

Influenza

Influenza segment was valued at US $8.15 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $18.72 billion by 2027. Influenza segment represented US $1.88 billion opportunity over 2019-2021 and estimated to create US $8.68 billion opportunity in 2027 over 2021.

HPV

HPV segment was valued at US $5.05 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $11.60 billion by 2027. HPV segment represented US $1.17 billion opportunity over 2019-2021 and estimated to create US $5.38 billion opportunity in 2027 over 2021.

Meningococcal Disease

Meningococcal Disease segment was valued at US $3.13 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $7.18 billion by 2027. Meningococcal Disease segment represented US $0.72 billion opportunity over 2019-2021 and estimated to create US $3.33 billion opportunity in 2027 over 2021.

Polio

Polio segment was valued at US $1.82 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $4.17 billion by 2027. Polio segment represented US $0.42 billion opportunity over 2019-2021 and estimated to create US $1.93 billion opportunity in 2027 over 2021.

Hepatitis

Hepatitis segment was valued at US $1.11 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $2.55 billion by 2027. Hepatitis segment represented US $0.26 billion opportunity over 2019-2021 and estimated to create US $1.18 billion opportunity in 2027 over 2021.

Rotavirus

Rotavirus segment was valued at US $0.68 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $1.56 billion by 2027. Rotavirus segment represented US $0.16 billion opportunity over 2019-2021 and estimated to create US $0.72 billion opportunity in 2027 over 2021.

MMR

MMR segment was valued at US $0.54 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $1.25 billion by 2027. MMR segment represented US $0.13 billion opportunity over 2019-2021 and estimated to create US $0.58 billion opportunity in 2027 over 2021.

Varicella

Varicella segment was valued at US $0.23 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $0.52 billion by 2027. Varicella segment represented US $0.05 billion opportunity over 2019-2021 and estimated to create US $0.24 billion opportunity in 2027 over 2021.

Herpes Zoster

Herpes Zoster segment was valued at US $0.15 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $0.35 billion by 2027. Herpes Zoster segment represented US $0.04 billion opportunity over 2019-2021 and estimated to create US $0.16 billion opportunity in 2027 over 2021.

Other Disease Indications

Other Disease Indications segment was valued at US $0.08 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $0.17 billion by 2027. Other Disease Indications segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.08 billion opportunity in 2027 over 2021.

Route of Administration

Introduction

In 2021, Intramuscular and Subcutaneous Administration segment has the highest revenue of US $35.50 billion and is expected to grow at CAGR of 9.67% by 2027 Oral Administration segment has highest cagr growth of 9.67%.

Intramuscular and Subcutaneous Administration

Intramuscular and Subcutaneous Administration segment was valued at US $28.84 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $66.20 billion by 2027. Intramuscular and Subcutaneous Administration segment represented US $6.66 billion opportunity over 2019-2021 and estimated to create US $30.70 billion opportunity in 2027 over 2021.

Oral Administration

Oral Administration segment was valued at US $22.68 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $52.06 billion by 2027. Oral Administration segment represented US $5.24 billion opportunity over 2019-2021 and estimated to create US $24.14 billion opportunity in 2027 over 2021.

Other Routes of Administration

Other Routes of Administration segment was valued at US $3.50 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $8.04 billion by 2027. Other Routes of Administration segment represented US $0.81 billion opportunity over 2019-2021 and estimated to create US $3.73 billion opportunity in 2027 over 2021.

Patient Type

Introduction

In 2021, Adult Patients segment has the highest revenue of US $38.20 billion and is expected to grow at CAGR of 9.67% by 2027 Pediatric Patients segment has highest cagr growth of 9.67%.

Pediatric Patients

Pediatric Patients segment was valued at US $23.98 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $55.05 billion by 2027. Pediatric Patients segment represented US $5.54 billion opportunity over 2019-2021 and estimated to create US $25.53 billion opportunity in 2027 over 2021.

Adult Patients

Adult Patients segment was valued at US $31.03 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $71.24 billion by 2027. Adult Patients segment represented US $7.17 billion opportunity over 2019-2021 and estimated to create US $33.04 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, North America segment has the highest revenue of US $28.12 billion and is expected to grow at CAGR of 9.67% by 2027 Europe segment has highest cagr growth of 9.67%.

North America

North America segment was valued at US $22.85 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $52.45 billion by 2027. North America segment represented US $5.28 billion opportunity over 2019-2021 and estimated to create US $24.32 billion opportunity in 2027 over 2021.

Europe

Europe segment was valued at US $12.99 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $29.83 billion by 2027. Europe segment represented US $3.00 billion opportunity over 2019-2021 and estimated to create US $13.83 billion opportunity in 2027 over 2021.

Asia

Asia segment was valued at US $13.07 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $30.01 billion by 2027. Asia segment represented US $3.02 billion opportunity over 2019-2021 and estimated to create US $13.92 billion opportunity in 2027 over 2021.

Rest of the World

Rest of the World segment was valued at US $6.10 billion in 2019 and is projected to grow at 9.67% CAGR over the forecast period to reach US $14.01 billion by 2027. Rest of the World segment represented US $1.41 billion opportunity over 2019-2021 and estimated to create US $6.50 billion opportunity in 2027 over 2021.